Advances in HER2-positive and HER2-low Breast Cancer

Course overview

This one-hour interactive, online CME/CMLE module is designed to help pathologists and laboratory professionals gain a deeper scientific understanding of recent advances in the diagnosis and management of HER2-positive and HER2-low breast cancer. It will address the following topics: * Recent advances in the clinical management of patients with HER2-positive breast cancer * Science and emerging evidence around HER2-low breast cancer * Application through case-based scenarios Learning Objectives: Upon completion of this activity, you should be able to: * Summarize recent clinical advances in the medical management of patients with HER2-positive breast cancer * Describe the science and emerging evidence around the diagnosis and treatment of HER2-low breast cancer Faculty: Aysegul A Sahin, MD Professor, Department of Pathology, Division of Pathology/Lab Medicine Section Chief of the Breast Pathology Section, Department of Pathology, Division of Pathology/Lab Medicine Director of Educational Operations, Department of Pathology, Division of Pathology/Lab Medicine The University of Texas MD Anderson Cancer Center Houston, TX Ali Brown, MD, FASCP Chief Officer, Medical Quality American Society for Clinical Pathology Washington, DC Erin Downs-Kelly, DO Director, Breast Pathology, Cleveland Clinic Cleveland, OH Shi Wei, MD Professor, Department of Pathology, Division of Pathology/Lab Medicine Head of Surgical Pathology Section, Division of Anatomic Pathology, Department of Pathology Director of Surgical Pathology Fellowship Program The University of Alabama at Birmingham Birmingham, AL